MCID: SPN021
MIFTS: 47

Spinal Meningioma

Categories: Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Spinal Meningioma

MalaCards integrated aliases for Spinal Meningioma:

Name: Spinal Meningioma 12 52 15 71
Meningioma 43 71
Meningioma, Benign, No Icd-O Subtype 71
Spinal Cord Meningioma 12
Meningioma, Spine 52

Classifications:



External Ids:

Disease Ontology 12 DOID:1138
MeSH 43 D008579
NCIt 49 C6935
UMLS 71 C0025286 C0347515 C1762616

Summaries for Spinal Meningioma

NIH Rare Diseases : 52 Spinal meningioma is a rare type of spinal cord cancer . The spinal cord is part of the central nervous system . This tumor often affects middle-aged women. Tumors of the spinal cord can be either primary or arise from other primary tumors (metastatic ), and are typically slow growing. The initial signs and symptoms include headache and recent onset of seizures . Other features are motor deficits, sensory deficits, pain, and sphincter dysfunction. The thoracic spine (middle back) is the most common site, followed by the cervical spine (neck). These tumors are rarely seen in the lumbar region (lower back). T he only proven risk factor in the development of meningioma is exposure to ionizing radiation . Also, patients with neurofibromatosis type 2 are at increased risk of developing meningioma. Surgery is the treatment of choice and complete tumor removal is reached in the vast majority of patients. The prognosis after surgical resection is excellent.

MalaCards based summary : Spinal Meningioma, also known as meningioma, is related to optic nerve sheath meningioma and lung meningioma. An important gene associated with Spinal Meningioma is SMARCE1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily E, Member 1), and among its related pathways/superpathways are Chromatin organization and Gastric cancer. The drugs Thrombin and Fibrin Tissue Adhesive have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and pituitary, and related phenotypes are Increased proliferation and mortality/aging

Related Diseases for Spinal Meningioma

Diseases related to Spinal Meningioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1092)
# Related Disease Score Top Affiliating Genes
1 optic nerve sheath meningioma 34.1 SMARCB1 NF2 LZTR1
2 lung meningioma 34.0 PGR NF2
3 angiomatous meningioma 34.0 TRAF7 SMARCE1
4 cerebral falx meningioma 33.9 SMARCB1 NF2
5 intraventricular meningioma 33.9 TRAF7 NF2
6 pediatric meningioma 33.9 TRAF7 NF2
7 rhabdoid meningioma 33.8 TRAF7 SMARCB1 NF2
8 frontal convexity meningioma 33.7 TRAF7 NF2
9 skull base meningioma 33.6 TRAF7 PGR NF2
10 intraorbital meningioma 33.6 NF2 LZTR1 DCAF1
11 olfactory groove meningioma 33.5 TRAF7 SMARCE1 NF2 LZTR1
12 benign meningioma 33.4 TRAF7 SMARCE1 PGR NF2
13 anterior cranial fossa meningioma 33.4 TRAF7 SMARCB1 NF2 LZTR1
14 clear cell meningioma 33.1 TRAF7 SMARCE1 SMARCB1 PGR NF2
15 schwannomatosis 1 32.8 SMARCB1 NF2
16 secretory meningioma 31.9 TRAF7 NF2
17 meningioma, radiation-induced 31.7 SMARCB1 PGR NF2
18 monosomy 22 31.3 SMARCB1 NF2
19 psammomatous meningioma 30.9 TRAF7 NF2
20 neuroma 30.6 SMARCB1 NF2 NF1
21 obstructive hydrocephalus 30.4 NF2 NF1
22 optic nerve glioma 30.4 NF2 NF1
23 meningothelial meningioma 30.3 TRAF7 SMARCE1 PGR NF2
24 microcystic meningioma 30.2 NF2 MIB1
25 fibrous meningioma 30.1 TRAF7 NF2
26 chordoid glioma 30.1 PGR NF2
27 neurilemmoma 30.1 SMARCB1 NF2 NF1 LZTR1
28 neurilemmoma of the fifth cranial nerve 30.0 NF2 NF1
29 spinal canal intradural extramedullary neoplasm 29.9 NF2 DCAF1
30 meningioma, familial 29.8 TRAF7 SMARCE1 SMARCB1 PGR NF2 NF1
31 neurofibromatosis, type iv, of riccardi 29.7 SMARCB1 NF2 NF1 LZTR1 DCAF1
32 rhabdoid cancer 29.7 SMARCE1 SMARCB1 PBRM1 ARID1B
33 transitional meningioma 29.7 TRAF7 SMARCE1 PGR NF2
34 skull base cancer 29.6 TRAF7 PGR NF2
35 supratentorial cancer 29.6 SMARCB1 NF2
36 brain meningioma 29.5 TRAF7 NF2 LZTR1 DCAF1
37 acoustic neuroma 29.4 SMARCB1 NF2 NF1 LZTR1
38 hypertrichosis 29.4 SMARCE1 SMARCB1 ARID1B
39 corpus callosum lipoma 29.4 SMARCB1 NF2 NF1
40 brain cancer 29.3 SMARCB1 NF2 NF1 DCAF1
41 plexiform neurofibroma 29.2 NF2 NF1
42 spinal canal and spinal cord meningioma 27.8 TRAF7 SMARCE1 SMARCB1 PHF10 PGR PBRM1
43 neurilemmomatosis 26.1 SMARCE1 SMARCB1 PHF10 PBRM1 NF2 NF1
44 childhood brain meningioma 12.3
45 chordoid meningioma 12.3
46 cavernous sinus meningioma 12.3
47 cerebral meningioma 12.3
48 tuberculum sellae meningioma 12.3
49 foramen magnum meningioma 12.3
50 choroid plexus meningioma 12.2

Graphical network of the top 20 diseases related to Spinal Meningioma:



Diseases related to Spinal Meningioma

Symptoms & Phenotypes for Spinal Meningioma

GenomeRNAi Phenotypes related to Spinal Meningioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased proliferation GR00094-A 8.62 NF2 SMARCB1

MGI Mouse Phenotypes related to Spinal Meningioma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 9.36 ACTL6B ARID1B DCAF1 LZTR1 MIB1 NF1

Drugs & Therapeutics for Spinal Meningioma

Drugs for Spinal Meningioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 251)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thrombin Approved, Investigational Phase 4
2 Fibrin Tissue Adhesive Phase 4
3 Hemostatics Phase 4
4 Coagulants Phase 4
5
Tranexamic Acid Approved Phase 3 1197-18-8 5526
6
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
7
Donepezil Approved Phase 3 120014-06-4 3152
8
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
9
Ondansetron Approved Phase 3 99614-02-5 4595
10
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
12
Cisatracurium Approved Phase 3 96946-41-7
13
Sevoflurane Approved, Vet_approved Phase 3 28523-86-6 5206
14
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
15
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
16
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
17
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
18
Histamine Approved, Investigational Phase 3 51-45-6 774
19
Cyproheptadine Approved Phase 3 129-03-3 2913
20
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
21 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
22 Antifibrinolytic Agents Phase 3
23 Progestins Phase 3
24 Nootropic Agents Phase 3
25 Cholinergic Agents Phase 3
26 Cholinesterase Inhibitors Phase 3
27 Liver Extracts Phase 3
28 Cola Phase 3
29 Emetics Phase 3
30 Narcotics Phase 3
31 Anesthetics, General Phase 3
32 Analgesics, Opioid Phase 3
33 Adjuvants, Anesthesia Phase 3
34 Anesthetics, Intravenous Phase 3
35 Antihypertensive Agents Phase 3
36 Analgesics Phase 3
37 Tocolytic Agents Phase 3
38 Anti-Arrhythmia Agents Phase 3
39 Vasoconstrictor Agents Phase 3
40 Anesthetics Phase 3
41 Anticonvulsants Phase 3
42 Central Nervous System Depressants Phase 3
43 Calcium, Dietary Phase 3
44 calcium channel blockers Phase 3
45 Gastrointestinal Agents Phase 3
46 Central Nervous System Stimulants Phase 3
47 Neurotransmitter Agents Phase 3
48 Dermatologic Agents Phase 3
49 Dopamine Uptake Inhibitors Phase 3
50 Dexmethylphenidate Hydrochloride Phase 3

Interventional clinical trials:

(show top 50) (show all 202)
# Name Status NCT ID Phase Drugs
1 Neurocognitive Outcome Assessment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial. Unknown status NCT03190122 Phase 4
2 Dissection of the Outer Layer of the Lateral Wall of the Cavernous Sinus Decreases Bleeding as Compared to Direct Tumor Attack in Middle Fossa Meningiomas: A Randomized Controlled Trial Unknown status NCT02863484 Phase 4
3 A Prospective, Randomized, Controlled Phase IV Study to Compare Bioseal Versus Standard of Care as an Adjunct to Hemostasis in Elective Brain Tumor Surgery Completed NCT02034799 Phase 4
4 PHASE 3 STUDY OF EFFICACY OF TRANEXAMIC ACID IN BRAIN TUMORS RESECTIONS Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
5 Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial Unknown status NCT00517959 Phase 3
6 Double Blind Randomized Trial of the Anti-Progestational Agent Mifepristone In The Treatment of Unresectable Meningioma Completed NCT03015701 Phase 3 Mifepristone
7 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
8 Prospective Study Of Patients With Recurrent Or Incomplete Excised Benign Intercranial Meningiomas For The Evaluation Of Treatment Result With Combined Proton And Photon Irradiation To Doses 55.8 Or 63.0 CGE Completed NCT02947984 Phase 3
9 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
10 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
11 Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma Recruiting NCT03180268 Phase 3
12 The Effect of Magnesium Sulphate on Intraoperative Blood Loss in Meningioma Patient Undergoing Craniotomy With Tumor Removal Not yet recruiting NCT03558516 Phase 3 Magnesium group;Normal saline group
13 Observation Versus Conventional-Fractionated Radiotherapy or Radiosurgery After Non-radical Surgery for Benign Intracranial Meningiomas: A Phase III Study Terminated NCT00104936 Phase 3
14 A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
15 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
16 Phase II Study of Hydroxyurea for the Treatment of Recurrent and/or Nonoperable Meningioma Unknown status NCT00006119 Phase 2 hydroxyurea
17 Phase II Trial of Observation for Low-Risk Meningiomas and of Radiotherapy for Intermediate- and High-Risk Meningiomas Unknown status NCT00895622 Phase 2
18 IMATINIB Plus Hydroxyurea in the Treatment of Recurrent or Progressive Meningiomas: a Randomized Phase II Study Unknown status NCT00904735 Phase 2 hydroxyurea;imatinib mesylate
19 Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas. Unknown status NCT02333565 Phase 2 Everolimus;Octreotide
20 Feasibility and Phase II Study Using Proton Radiation For WHO Grade I-III Meningiomas and Hemangiopericytomas Unknown status NCT01117844 Phase 1, Phase 2
21 Proton Radiation for Low Grade Gliomas Unknown status NCT01024907 Phase 1, Phase 2
22 Trabectedin for Recurrent Grade II or III Meningioma: a Randomized Phase II Study of the EORTC Brain Tumor Group Completed NCT02234050 Phase 2 Trabectedin
23 Phase II Study of Hydroxyurea for Unresectable Meningioma Completed NCT00003590 Phase 2 hydroxyurea
24 A Phase II Trial of PTK-787 in Recurrent or Progressive Meningiomas Completed NCT00348790 Phase 2 vatalanib
25 Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma Completed NCT00859040 Phase 2 SOM230C
26 Adjuvant Postoperative High-Dose Radiotherapy for Atypical and Malignant Meningioma: a Phase-II and Observation Study Completed NCT00626730 Phase 2
27 ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs Completed NCT00025675 Phase 2 gefitinib
28 A Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent/Progressive Meningioma Completed NCT00354913 Phase 2 hydroxyurea;imatinib mesylate
29 Phase II Trial of STI571 (NSC 716051) in Patients With Recurrent Meningioma Completed NCT00045734 Phase 2 imatinib mesylate
30 Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Completed NCT00589784 Phase 2 Sunitinib
31 A Feasibility Study of Armodafinil for Brain Radiation-Induced Fatigue Completed NCT01032200 Phase 2 Armodafinil
32 Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas Completed NCT00010049 Phase 1, Phase 2 imatinib mesylate
33 Levetiracetam and Pregabalin for Monotherapy in Patients With Brain Tumors and Seizures. A Phase II Randomized Study. Completed NCT00629889 Phase 2 levetiracetam;pregabalin
34 A Phase I/II Trial of OSI-774 in Patients With Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy Completed NCT00045110 Phase 1, Phase 2 erlotinib hydrochloride
35 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
36 A Phase II Trial of Rebeccamycin Analogue (NSC #655649) in Children With Solid Tumors Completed NCT00006102 Phase 2 becatecarin
37 Phase II Treatment of Children With Newly Diagnosed Malignant Central Nervous System Tumors With Temozolomide Prior to Radiation Therapy Completed NCT00005955 Phase 2 temozolomide
38 Donepezil and EGb761 in Improving Neurocognitive Function in Patients Who Have Previously Undergone Radiation Therapy for Primary Brain Tumor or Brain Metastases Completed NCT00070161 Phase 2 donepezil hydrochloride
39 A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas Completed NCT00004868 Phase 1, Phase 2 semaxanib
40 Phase I Study of At-Labeled Anti-Tenascin Human/Mouse Chimeric Monoclonal Antibody 81C6 (ch81C6) Via Surgically Created Cystic Resection Cavity in the Treatment of Patients With Primary or Metastatic Brain Tumors Completed NCT00003461 Phase 1, Phase 2
41 Phase II Trial of Irinotecan in Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
42 Phase II Study to Evaluate the Efficacy of Recombinant Interferon-Alpha in the Treatment of Recurrent Unresectable Meningiomas and Malignant Meningiomas Completed NCT00002965 Phase 2
43 Phase II Trial Of High Dose Cyclophosphamide, Cisplatin And Carmustine With Stem Cell Reconstitution Followed By Specific Cellular Therapy In Patients With Recurrent Or Refractory Brain Tumors Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
44 Combination of Hydroxyurea and Verapamil for Refractory Meningiomas Completed NCT00706810 Phase 2 Hydroxyurea;Verapamil
45 Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma Recruiting NCT03279692 Phase 2 Pembrolizumab
46 A Single Arm, Open-label, Multicenter Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma Recruiting NCT03971461 Phase 2 Lutathera
47 An Open-Label Phase II Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma Recruiting NCT02648997 Phase 2 Nivolumab - 240 mg;Ipilimumab - 3 mg/kg;Nivolumab - 480 mg;Nivolumab - 1 mg/kg
48 A Phase II, Open-label, Single Arm Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma Recruiting NCT03016091 Phase 2 Pembrolizumab
49 A Single Arm Phase II Study Of The Dual mTORC1/mTORC2 Inhibitor Vistusertib (AZD2014) Provided On An Intermittent Schedule For Sporadic Patients With Grade II-III Meningiomas That Recur Or Progress After Surgery And Radiation Recruiting NCT03071874 Phase 2 AZD2014
50 Effect of Hippocampal Sparing on Neurocognitive Functions and Quality of Live in Patients Irradiated in the Neurocranial Area Recruiting NCT01849484 Phase 2

Search NIH Clinical Center for Spinal Meningioma

Cochrane evidence based reviews: meningioma

Genetic Tests for Spinal Meningioma

Anatomical Context for Spinal Meningioma

MalaCards organs/tissues related to Spinal Meningioma:

40
Brain, Spinal Cord, Pituitary, Bone, Breast, Lung, Thyroid

Publications for Spinal Meningioma

Articles related to Spinal Meningioma:

(show top 50) (show all 14013)
# Title Authors PMID Year
1
Mania and psychosis associated with right parietal meningioma. 61
31698993 2020
2
Sellar surprises: a single-centre experience of unusual sellar masses. 61
31910151 2020
3
Indications and outcome in surgically treated asymptomatic meningiomas: a single-center case-control study. 61
32016587 2020
4
Treatment of traumatic intracranial aneurysm: Experiences at a single center. 61
31812032 2020
5
The challenge of overcoming the language barrier for brain tumor awake surgery in migrants: a feasibility study in five patient cases. 61
31650333 2020
6
Metastatic meningioma: Case report of a WHO grade I meningioma with liver metastases and review of the literature. 61
31762868 2020
7
Corrigendum to "Gamma Knife stereotactic radiosurgery for cerebellopontine angle meningioma" [Clin. Neurol. Neurosurg. 187 (2019) 105557]. 61
31928856 2020
8
Spectrochemical differentiation of meningioma tumours based on attenuated total reflection Fourier-transform infrared (ATR-FTIR) spectroscopy. 61
31865413 2020
9
Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial. 61
31969329 2020
10
Meningioma in mature cystic teratoma of the ovary: clinical and computed tomography findings. 61
32024553 2020
11
SNHG1/miR-556-5p/TCF12 feedback loop enhances the tumorigenesis of meningioma through Wnt signaling pathway. 61
31692066 2020
12
Clinicoradiologic Characteristics of Temporal Bone Meningioma: Multicenter Retrospective Analysis. 61
32011010 2020
13
How long is the tail end of the learning curve? Results from 1000 consecutive endoscopic endonasal skull base cases following the initial 200 cases. 61
32032942 2020
14
Differentiating intracranial solitary fibrous tumor/hemangiopericytoma from meningioma using diffusion-weighted imaging and susceptibility-weighted imaging. 61
31673748 2020
15
[Intra-cranial meningiomas - Management of the patients in the microsurgery era]. 61
32022496 2020
16
Predictors of preoperative endovascular embolization of meningiomas: subanalysis of anatomic location and arterial supply. 61
31308198 2020
17
Pterional Craniotomy for Resection of Clinoidal Meningioma Associated With an Aerated Anterior Clinoid Process: 2-Dimensional Operative Video. 61
31120131 2020
18
Letter: Treatment of Asymptomatic Meningioma With Gamma Knife Radiosurgery: Long-Term Follow-up With Volumetric Assessment and Clinical Outcome. 61
32023346 2020
19
In Reply: Treatment of Asymptomatic Meningioma With Gamma Knife Radiosurgery: Long-Term Follow-up With Volumetric Assessment and Clinical Outcome. 61
32023347 2020
20
Letter regarding "Cognitive outcomes in meningioma patients undergoing surgery: individual changes over time and predictors of late cognitive functioning". 61
32027373 2020
21
Meningioma can lead to pre-operative cognitive alterations even if localized in sensorimotor areas: A multimodal MRI-neuropsychological study in a series of 46 patients. 61
31790726 2020
22
MN1, FOXP1 and hsa-miR-181a-5p as prognostic markers in acute myeloid leukemia patients treated with intensive induction chemotherapy and autologous stem cell transplantation. 61
31927137 2020
23
Utility of dual-energy CT for predicting the vascularity of meningiomas. 61
31864141 2020
24
Inflammatory Myofibroblastic Tumor of Spinal Canal: Brief Case Report. 61
31962352 2020
25
Metabolomic Profile of Aggressive Meningiomas by Using High-Resolution Magic Angle Spinning Nuclear Magnetic Resonance. 61
31679342 2020
26
Brachytherapy with surgical resection as salvage treatment for recurrent high-grade meningiomas: a matched cohort study. 61
31745706 2020
27
A retrospective survey on canine intracranial tumors between 2007 and 2017. 61
31801930 2020
28
Gamma Knife Radiosurgery for Anterior Clinoid Process Meningiomas: A Series of 61 Consecutive Patients. 61
31562964 2020
29
Evolving Strategies for Resection of Sellar/Parasellar Synchronous Tumors via Endoscopic Endonasal Approach: A Technical Case Report and Systematic Review of the Literature. 61
31476461 2020
30
Treatment of complex intracranial pathologies with transcirculation endovascular approaches. 61
31987753 2020
31
A recurrent case of pituicytoma 16 years later. 61
31964155 2020
32
Shunt-Bronchial Fistula with Coughing Up and Swallowing of Cerebrospinal Fluid: Rare Complication of Ventriculopleural Shunt. 61
31872190 2020
33
Craniocervical Rosai-Dorfman Disease Involving the Vertebral Artery: Case Report and Literature Review. 61
31550540 2020
34
Artery of Davidoff and Schechter Supply in Dural Arteriovenous Fistulas. 61
31974076 2020
35
Clinical features and surgical outcomes of high-grade spinal meningiomas: Report of 19 cases and literature review. 61
31983641 2020
36
Cyclin E1 expression and malignancy in meningiomas. 61
31945623 2020
37
Postoperative Euglycemic Diabetic Ketoacidosis and Encephalopathy Related to SGLT-2 Inhibitors: A Case Report and Discussion of Diabetes Treatment and "Sweet Pee Encephalopathy" in Perioperative Hospital Management. 61
31839866 2020
38
Inter-Observer Variability in Target Volume Delineations of Benign and Metastatic Brain Tumours for Stereotactic Radiosurgery: Results of a National Quality Assurance Programme. 61
31301960 2020
39
Predictors of recurrence and high growth rate of residual meningiomas after subtotal resection. 61
31899874 2020
40
The Clinical Significance of Soluble Programmed Cell Death-Ligand 1 (sPD-L1) in Patients With Gliomas. 61
32038986 2020
41
A practical predictor of the growth potential of benign meningiomas: Hypointensity of surface layer in T2-weighted magnetic resonance imaging. 61
32018148 2020
42
Adrenal Cortical Adenoma in the Spinal Canal: A Case Report and Review of the Literature. 61
31127594 2020
43
Clinicopathological characteristics of histiocytic sarcoma affecting the central nervous system in dogs. 61
31919895 2020
44
Successful resolution of the ophthalmic manifestations of a falcotentorial meningioma through Cerebrospinal fluid diversion. 61
31843434 2020
45
Individual-patient prediction of meningioma malignancy and survival using the Surveillance, Epidemiology, and End Results database. 61
32025573 2020
46
[A Case of Atypical Meningioma with Liver Metastasis at 9 Years after Initial Surgery]. 61
31983690 2020
47
Intracranial isolated varix mimicking a meningioma: the relevance of modern MRI techniques for reliable diagnosis. 61
31967208 2020
48
Concurrent Pituicytoma, Meningioma, and Cavernomas After Cranial Irradiation for Childhood Acute Lymphoblastic Leukemia. 61
31904435 2020
49
MicroRNA-195 Functions as a Tumor Suppressor by Directly Targeting Fatty Acid Synthase in Malignant Meningioma. 61
31927122 2020
50
How I do it: contralateral supraorbital approach for tuberculum sellae meningioma. 61
31900657 2020

Variations for Spinal Meningioma

Expression for Spinal Meningioma

Search GEO for disease gene expression data for Spinal Meningioma.

Pathways for Spinal Meningioma

Pathways related to Spinal Meningioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.4 SMARCE1 SMARCB1 PBRM1 ARID1B ACTL6B
2
Show member pathways
11.89 SMARCE1 SMARCB1 PHF10 PGR PBRM1 DPF1
3
Show member pathways
11.1 SMARCE1 SMARCB1 ARID1B ACTL6B

GO Terms for Spinal Meningioma

Cellular components related to Spinal Meningioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 10.06 SMARCE1 SMARCB1 PHF10 PGR PBRM1 NF2
2 nuclear chromatin GO:0000790 9.77 SMARCE1 SMARCB1 PHF10 PGR DPF1
3 histone acetyltransferase complex GO:0000123 9.4 PHF10 DPF1
4 npBAF complex GO:0071564 9.33 SMARCE1 SMARCB1 PHF10
5 brahma complex GO:0035060 9.26 SMARCB1 ARID1B
6 SWI/SNF complex GO:0016514 9.26 SMARCE1 SMARCB1 ARID1B ACTL6B
7 nBAF complex GO:0071565 9.02 SMARCE1 SMARCB1 DPF1 ARID1B ACTL6B

Biological processes related to Spinal Meningioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nervous system development GO:0007399 9.8 SMARCE1 SMARCB1 PHF10 DPF1 ARID1B ACTL6B
2 negative regulation of cell proliferation GO:0008285 9.71 SMARCB1 PBRM1 NF2 NF1
3 chromatin organization GO:0006325 9.63 SMARCE1 SMARCB1 PBRM1 DCAF1 ARID1B ACTL6B
4 spinal cord development GO:0021510 9.48 NF1 ACTL6B
5 negative regulation of MAPK cascade GO:0043409 9.46 NF2 NF1
6 negative regulation of Ras protein signal transduction GO:0046580 9.43 NF1 LZTR1
7 nucleosome disassembly GO:0006337 9.43 SMARCE1 SMARCB1 PBRM1
8 negative regulation of cell-matrix adhesion GO:0001953 9.37 NF2 NF1
9 ATP-dependent chromatin remodeling GO:0043044 9.26 SMARCE1 SMARCB1 PBRM1 ACTL6B
10 chromatin remodeling GO:0006338 9.02 SMARCE1 SMARCB1 PBRM1 ARID1B ACTL6B

Molecular functions related to Spinal Meningioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription coactivator activity GO:0003713 8.92 SMARCE1 SMARCB1 ARID1B ACTL6B

Sources for Spinal Meningioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....